This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

NeoStem Welcomes David Altarac, M.D., As Vice President, Regulatory Affairs

Stocks in this article: NBS

NEW YORK, Jan. 28, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today the appointment of Dr. David Altarac as Vice President, Regulatory Affairs. In this position, Dr. Altarac will lead NeoStem's regulatory affairs operations as it grows in connection with the Company's therapeutic pipeline expansion in 2014 and beyond.

NeoStem is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by replacing and repairing damaged tissue, cells and organs and restoring their functionality to normal. The development of novel and proprietary cell therapy products is built around a robust intellectual property portfolio, and also utilizes the deep experience as well as engineering and innovation solutions of NeoStem's subsidiary, Progenitor Cell Therapy ("PCT"), a premier contract development and manufacturing organization that is a pioneer in the cell therapy industry, NeoStem continues to expand its clinical team. In August, Dr. Douglas W. Losordo, a leader in cell therapy and a cardiologist regarded for his career-long efforts to develop novel therapeutics, joined the Company as its Chief Medical Officer. As Vice President, Clinical Development and New Technologies, Dr. Jonathan Sackner-Bernstein will continue to oversee the Company's clinical development programs and his role will expand to include evaluation of opportunities to acquire or develop new technologies.

"Dr. Altarac brings to the Company an impressive resume of experience in U.S. and global regulatory affairs, operations, labeling and organizational design and we are thrilled to have his expertise as we expand our clinical development team," commented Dr. Douglas Losordo.

Dr. Altarac comes to NeoStem after a successful 13 year tenure at Merck and Company, Inc. where he most recently held the position of Vice President, Regulatory Affairs Emerging Markets R & D at Merck Research Labs. In that position he was responsible for overseeing the regulatory affairs (operations and strategy) for Merck's Emerging Markets ("EM") group, which originally was comprised of Brazil, Russia, India, China, Korea, Turkey, and Mexico. One of his first efforts in that position was the integration of the Most of World regulatory organization into the company's EM Regulatory team to form a collaborative, global R & D regulatory organization with more than 325 staff operating in over 125 countries. He also worked to develop robust interfaces with regulatory support teams throughout Merck's business units including Worldwide Product Labeling, Global Regulatory Operations, Global Safety, and Merck Enterprise groups including Global Human Health, Merck Manufacturing Division, Merck Consumer Care and Merck Vaccines Division.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,877.37 +49.62 0.28%
S&P 500 2,072.30 -0.53 -0.03%
NASDAQ 4,807.0470 +19.73 0.41%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs